Research programme: galectin-3 inhibitors - G3 Pharmaceuticals

Drug Profile

Research programme: galectin-3 inhibitors - G3 Pharmaceuticals

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator G3 Pharmaceuticals; University Medical Center Groningen; University of Michigan Medical School
  • Class Cardiovascular therapies; Polysaccharides
  • Mechanism of Action Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Kidney disorders

Most Recent Events

  • 14 Sep 2017 Lead optimisation is ongoing in Kidney disorders and Cardiovascular disorders (PO) (9222922; 3271522)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top